17 July 2026
17 July 2026
MSD has outpaced rivals to market the first PCSK9 inhibitor in pill form for patients with high cholesterol.
Novo Nordisk is relying on first-mover advantage in the obesity pill arena to close the gap on Eli Lilly.
This acquisition marks Lilly’s first move into the psychedelic space as the pharma curates a diversified pipeline.
The pharma industry welcomed the pledge, which marked the first-time drug IP has explicitly been stated in a free trade agreement.
The JCVI review incorporated recent data on the effectiveness in adolescents vaccinated against MenB in infancy.
Kerendia will become available to English patients with chronic heart failure with preserved or mildly reduced ejection fraction.
The traditional FDA approval was supported by results from the Phase III APPLAUSE-IgAN study.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
